$90 Million to U. of C. Meant to 'Alter the Course of Cancer'
The Chicago Tribune reports that cancer researchers at the University of Chicago will get a substantial boost Monday, when an international nonprofit plans to announce that the university and five other leading institutions will each receive $90 million to advance new treatments aimed at eradicating cancer.
The $540 million gift from Ludwig Cancer Research, a fund created by the late billionaire Daniel Ludwig, comes at a time when government and private funding for medical research is on the decline.
"We're here to alter the course of cancer," said Ed McDermott, a Ludwig trustee and president and CEO of the Ludwig Institute for Cancer Research, a sister organisation that has more than 600 cancer researchers at dedicated labs around the world. "This funding will be available for those scientists for the indefinite future without having to worry about whether their research is going to be funded next year."
The gift adds to a $120 million endowment in 2006 that created Ludwig Centers at the U. of C., Johns Hopkins University, Harvard University, Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center and Stanford University.
The Chicago research center, headed by radiation oncologist Dr Ralph Weichselbaum and Geoffrey Greene, a molecular biologist, has now received a total of $110 million from Ludwig, which it says should fund in perpetuity continuing study of the disease.
The Ludwig endowment comes at a crucial time for research institutions like the U. of C., which are finding it increasingly difficult to secure grants and other funding to support biomedical research.
"At this time in the history of federal research dollars, the Ludwig funding has created a remarkable opportunity for me and others here to pursue topics, technologies and other initiatives that we just can't get through federal funding," Greene said in an interview. "It's really such a tremendous advantage."
Greene and Weichselbaum said the new funding will help the Chicago research center accelerate and advance its continuing body of research on metastasis, the process by which cancer cells migrate from a primary tumor to distant sites in the body.
The U. of C. plans to use the money to hire researchers, technicians and scientists and purchase equipment. The grant also provides a unique flexibility to pursue unconventional research that other entities often do not fund.
"It's pivotal funding at a time when I think it would have been very hard (to continue this research) otherwise," Weichselbaum said. "The entirety of science revolves around fresh ideas and new infusions of talent, and I think universities are finding this increasingly difficult."
The Ludwig Center is inside the U. of C.'s Gwen and Jules Knapp Center for Biomedical Discovery, which opened in 2009.
The latest funding should enable each center to build a self-sustaining endowment that will yield about $4 million to $5 million in annual research funds in the near term, with amounts growing in later years as their endowments grow, the fund said.
Each university will be responsible for managing its own endowment investments.
Although each center has its own specific focus in the disease category, they commonly collaborate to share theories and discoveries about the nature of cancer and better ways to treat it.
"The whole purpose of this funding is meant to be transformative," McDermott said. "It is meant to relieve investigators from being wholly reliant on short-term grant funding to enable more innovative, higher-risk research."
In a typical grant process, researchers have shorter time frames — typically about three years — to conduct studies and show results in order to get re-funded, McDermott said. The practice "tends to encourage incrementalism."
Instead, he said, the Ludwig money aims for major breakthroughs.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance